Browsing: Phase

Rare disease clinical trials present unique operational and recruitment challenges, particularly when patient populations are small, diagnoses are delayed, and treatment windows are narrow. In a Phase III study evaluating an investigational therapy for anti-GBM (Goodpasture’s) disease, success depended on identifying and enrolling eligible patients quickly while coordinating activities across a global network of sites.…

Craigavon-headquartered pharmaceutical company Galenhas launched Galsana, a new global brand that will support the continued growth and development of its specialist rare metabolic disease business and future innovation across the portfolio

Boulder, Colorado-based Enveda has reported Phase I results for ENV-308, an oral small molecule designed to mimic Lac-Phe, a hormone the body produces during high-intensity exercise, positioning the drug as a potential maintenance therapy for patients who discontinue GLP-1 receptor agonists and subsequently regain weight

Exceptional safety was observed across 88 healthy volunteers. Phase 2 plans to test whether ENV-308 can help people maintain their weight after stopping GLP-1s

|| A view of JW Pharmaceutical’s headquarters. Photo courtesy of JW Pharmaceutical

Competition is intensifying among the drugmakers chasing Eli Lilly and Novo Nordisk, which dominate the global obesity drug market. With Phase 3 results and regulatory filings for major candidates expected to follow one after another beginning next year, the next one to two years are set to be a watershed for the market landscape

-ASC36_35FDC, a once-monthly subcutaneous (SQ) fixed dose combination (FDC) injection of ASC36 and ASC35, is a potentially first-in-class drug candidate which targets three validated targets of amylin receptor, GLP-1R and GIPR

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free dailyPharmaVoice newsletter

Neurocrine Biosciences has initiated a Phase 1 clinical trial to test the safety and tolerability of NBIP-‘1968, a novel triple agonist drug targeting GLP-1, GIP, and glucagon receptors for obesity treatment. This investigational drug aims to address obesity by engaging three metabolic mechanisms to regulate appetite, energy balance, and glycemic control. The study will involve…

Aug. 7, 2026 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-‘1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity